PD-1 Modulation and Uses Therof for Modulating HIV Replication and HIV Therapy
OHSU # 1509
Value Proposition: Current treatments of HIV that seek to block one or more steps involved in viral replication tend to have serious side effects, complex regimens and require lifelong adherence. Furthermore, the treatments fail to eliminate latently infected cells in which the virus is not actively replicating. Thus, there is a need for novel strategies for modulating HIV replication.
Technology Information: Programmed cell death protein 1 (PD-1) is a Type I membrane protein that plays an important role in down regulating the immune system by preventing the activation of T-cells
The present technology relates to the modulation of HIV infection, and more particularly to methods and compositions for inhibiting or enhancing HIV replication. It provides a method for controlling active viral infection by inhibiting HIV viral replication with a Programmed Death-1 (PD-1) agonist.
In another aspect, the technology provides a use of a PD-1 inhibitor for increasing HIV replication in a cell. In this respect, the latently infected cells can become detectible by current HIV antiretroviral agents due to the increase in virus replication.
Basic Market Information: Stimulated by new drug launches and the increasing prevalence of HIV, the combined sales value of anti-HIV drugs is expected to rise over 40% in the several years from $11.9 billion in 2013 to $16.8 billion in 2022.
United States Patent Application No. 14/531,403
The patent rights are available for licensing.
For more information, contact:
Senior Director, Technology Transfer